

ANNEXIN PHARMACEUTICALS SELECTED TO PRESENT AT THE EYECCELERATOR CONFERENCE AND MEETS WITH THE MEDICAL ADVISORY BOARD IN ORLANDO

Annexin Pharmaceuticals AB has been selected from “a record-breaking pool of applicants” to present at Eyecelerator, a meeting in connection with the annual AAO Congress (American Academy of Ophthalmology) 2025 in Orlando, USA. During the conference, Annexin will also meet with its newly appointed Medical Advisory Board to discuss strategy for designing phase 2b and phase 3 studies in Retinal Vein Occlusion (RVO) and subsequently seek advice from FDA, among others.

Eyecelerator is an internationally recognized innovation and business forum focused on bringing together scientific and clinical excellence, innovative companies in ophthalmology, strategic partners and investors. It will be held in conjunction with the scientific meeting of the American Academy of Ophthalmology between October 17-20. The company's presence at Eyecelerator aims to increase awareness of Annexin and the company's clinical development program in ophthalmology, as well as to meet potential partners in both the life science industry and the capital market.

The company has recently appointed a **Medical Advisory Board** that will now meet in person at the AAO conference to discuss both the overall development strategy and detailed study-related plans for ANXV in RVO. The Board is expected to provide important advice and guidance ahead of meetings with regulatory authorities, including the US FDA, regarding the most appropriate endpoints to evaluate in continued clinical studies ahead of a future product approval. This is also important in the context of partnership discussions.

"We are very happy to have been selected to present at Eyecelerator. It is a unique opportunity to meet leading ophthalmologists, industry players and potential partners in an arena that is focused on innovation in eye diseases. The conference is a strategically important platform to present our promising data with the drug candidate ANXV in RVO, as well as our ongoing clinical phase 2a study where we are also evaluating ANXV as a treatment for the serious eye disease diabetic retinopathy for the first time," says Anders Haegerstrand, CEO of Annexin Pharmaceuticals.

"The first formal meeting with the company's newly established Medical Advisory Board, consisting of leading experts in the field, so-called "key opinion leaders" (KOLs), is a milestone. These KOLs, have a deep understanding and broad experience in clinical drug development and treatment of patients with vision threatening retinal diseases. We look forward to receiving their views on our plans so that we are optimally prepared for meetings with regulatory authorities, such as FDA," says Anna Frostegård, Chief Scientific and Medical Officer at Annexin Pharmaceuticals.

For further information, please contact:

Anders Haegerstrand, CEO

Phone: +46 (0)70 575 50 37

Mail: anders.haegerstrand@annexinpharma.com

About Annexin Pharmaceuticals AB

Annexin Pharmaceuticals AB is a leading biotechnology company in the Annexin A5 field for the treatment of various diseases. The company's biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for treatment of patients with injuries and inflammation of the blood vessels, but also for cancer. The company has an extensive patent portfolio for the treatment of diseases with Annexin A5 and for production of Annexin A5. The Company is based in Stockholm, Sweden and listed on Nasdaq First North Growth Market, under the ticker ANNX. Redeye is the company's Certified Adviser.

Attachments

[Annexin Pharmaceuticals selected to present at the Eyecelerator conference and meets with the Medical Advisory Board in Orlando](#)